Atlas Molecular Pharma announces the start of human clinical trial
The Basque company begins the first phase I clinical trial with ATL-001 for the treatment of congenital erythropoietic porphyria (CEP) Atlas Molecular Pharma (Atlas), a spin-off from the CIC bioGUNE research center and led by Óscar Millet and Joaquín Castilla, was founded in 2015 with the aim of developing new pharmacological chaperones for the treatment […]
Atlas Molecular Pharma, closer to make the dream of having a drug for Congenital Erythropoietic Porphyria come true
The phase 1 clinical trial to test the new drug in humans was authorized and will begin soon in the United States Congenital Erythropoietic Porphyria is an ultra-rare, severe, and highly debilitating pathology with no therapeutic options in the market nor in development until now. The disease affects less than one person per million […]
